Physician profile
Karen Beigel
NPI 1225175631
$7,266.06
in general payments reported to CMS, 2019-2025
39 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,660 · 2022: $1,600 · 2023: $2,176 · 2024: $1,522 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,005.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,863.87 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $980.43 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $593.76 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $503.10 | 2021-2024 | Jardiance |
| Abbvie INC. | $467.61 | 2021-2024 | |
| Abbott Laboratories | $389.17 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $285.70 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $219.36 | 2021 | |
| Esperion Therapeutics, INC. | $205.92 | 2021 | |
| Amgen INC. | $201.16 | 2021-2024 | Otezla, Repatha, Prolia |
| Boston Scientific Corporation | $145.88 | 2023 | Watchman Flx |
| Janssen Biotech, INC. | $124.39 | 2025 | Rybrevant, Carvykti |
| Merck Sharp & Dohme LLC | $116.57 | 2021-2024 | Steglatro, Belsomra, Gardasil 9 |
| Biohaven Pharmaceutical Holding Company LTD. | $116.38 | 2022 | |
| Eisai INC. | $108.11 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Beigel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.